Abstract
Background: Inter-individual differences in metabolism of psychotropic drugs have a major impact on clinical outcome. Important discoveries about polymorphic cytochrome P450 enzymes (CYP) raise expectations that pharmacogenetic testing might become a routine tool to identify patients at risk of adverse drug reactions (ADR) or therapeutic failures.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
